Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023.
Tamargo J, Agewall S, Borghi C, Ceconi C, Cerbai E, Dan GA, Ferdinandy P, Grove EL, Rocca B, Magavern E, Sulzgruber P, Semb AG, Sossalla S, Niessner A, Kaski JC, Dobrev D. Tamargo J, et al. Among authors: niessner a. Eur Heart J Cardiovasc Pharmacother. 2024 May 4;10(3):219-244. doi: 10.1093/ehjcvp/pvae013. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 38379024 Review.
Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke.
Sulzgruber P, Wassmann S, Semb AG, Doehner W, Widimsky P, Gremmel T, Kaski JC, Savarese G, Rosano GMC, Borghi C, Kjeldsen K, Torp-Pedersen C, Schmidt TA, Lewis BS, Drexel H, Tamargo J, Atar D, Agewall S, Niessner A. Sulzgruber P, et al. Among authors: niessner a. Eur Heart J Cardiovasc Pharmacother. 2019 Jul 1;5(3):171-180. doi: 10.1093/ehjcvp/pvz016. Eur Heart J Cardiovasc Pharmacother. 2019. PMID: 31119266 Review.
Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases.
Savarese G, Reiner MF, Uijl A, D'Amario D, Agewall S, Atar D, Baumgartner I, Borghi C, De Carlo M, Drexel H, Kaski JC, Kjeldsen KP, Kucher N, Lund LH, Niessner A, Semb AG, Schmidt TA, Sulzgruber P, Tamargo J, Vitale C, Wassmann S, Aboyans V, Lewis BS. Savarese G, et al. Among authors: niessner a. Eur Heart J Cardiovasc Pharmacother. 2020 Apr 1;6(2):86-93. doi: 10.1093/ehjcvp/pvz036. Eur Heart J Cardiovasc Pharmacother. 2020. PMID: 31392312 Free article.
The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS, Kjeldsen KP, Niessner A, Wassmann S, Sulzgruber P, Borry P, Agewall S, Semb AG, Savarese G, Pirmohamed M, Caulfield MJ. Magavern EF, et al. Among authors: niessner a. Eur Heart J Cardiovasc Pharmacother. 2022 Jan 5;8(1):85-99. doi: 10.1093/ehjcvp/pvab018. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 33638977
Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
Krogager ML, Kragholm K, Thomassen JQ, Søgaard P, Lewis BS, Wassmann S, Baumgartner I, Ceconi C, Schmidt TA, Kaski JC, Drexel H, Semb AG, Agewall S, Niessner A, Savarese G, Kjeldsen KP, Borghi C, Tamargo J, Torp-Pedersen C. Krogager ML, et al. Among authors: niessner a. Eur Heart J Cardiovasc Pharmacother. 2021 Nov 3;7(6):557-567. doi: 10.1093/ehjcvp/pvab038. Eur Heart J Cardiovasc Pharmacother. 2021. PMID: 33956964 Review.
Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS, Kjeldsen KP, Niessner A, Wassmann S, Sulzgruber P, Borry P, Agewall S, Semb AG, Savarese G, Pirmohamed M, Caulfield MJ. Magavern EF, et al. Among authors: niessner a. Eur Heart J Cardiovasc Pharmacother. 2022 Jan 5;8(1):100-103. doi: 10.1093/ehjcvp/pvab063. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 34463331
Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
Tamargo J, Kjeldsen KP, Delpón E, Semb AG, Cerbai E, Dobrev D, Savarese G, Sulzgruber P, Rosano G, Borghi C, Wassmann S, Torp-Pedersen CT, Agewall S, Drexel H, Baumgartner I, Lewis B, Ceconi C, Kaski JC, Niessner A. Tamargo J, et al. Among authors: niessner a. Eur Heart J Cardiovasc Pharmacother. 2022 Jun 8;8(4):406-419. doi: 10.1093/ehjcvp/pvac005. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 35092425 Review.
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022.
Tamargo J, Agewall S, Borghi C, Ceconi C, Cerbai E, Dan GA, Ferdinandy P, Grove EL, Rocca B, Sulzgruber P, Semb AG, Sossalla S, Niessner A, Kaski JC, Dobrev D. Tamargo J, et al. Among authors: niessner a. Eur Heart J Cardiovasc Pharmacother. 2023 May 11;9(4):353-70. doi: 10.1093/ehjcvp/pvad034. Online ahead of print. Eur Heart J Cardiovasc Pharmacother. 2023. PMID: 37169875 Free PMC article.
205 results